SALSA MLPA P207 F9 probemix - 50 reactions

application: Factor IX deficiency, Christmas disease
region: F9 Xq27.1 Detailní informace

Cena s DPH € 573.54
Cena bez DPH € 474.00
 50 react
Dostupnost Skladem
Kód produktu P207-050R

Nejnovější informace o produktu naleznete exklusivně na stránkách výrobce MRC-Holland www.mlpa.com (nové okno)

Detailní popis SALSA MLPA P207 F9 probemix - 50 reactions

P207-025R SALSA MLPA P207 F9 probemix – 50 rxn

description
The term hemophilia is used in reference to hemophilia A (Factor VIII deficiency); hemophilia B or Christmas disease (factor IX deficiency) and von Willebrand disease (von Willebrand factor deficiency). Hemophilia A and B are both X-linked disorders.

Factor IX Deficiency or Christmas disease (plasma thromboplastic component deficiency) is the result of a hereditary defect in the F9 gene. F9, located on chromosome Xq27.1 and responsible for hemophilia B, is not allelic and consist of two polypeptide chains referred to as the L (light) and H (heavy) chains. Thus, two non-allelic forms of hemophilia B or Factor IX deficiency may exist. Factor IX circulates as an inactive zymogen until proteolytic release of its 'activation peptide' allows it to assume the conformation of an active serine protease. Its role in the blood coagulation cascade is to activate Factor X through interactions with calcium, membrane phospholipids, and Factor VIII. Another procoagulant serine protease activated molecule is Factor VII which also plays an important role in blood clotting. Upon injury, a complex of Factor XII and tissue factor (TF) is formed. This complex triggers the activation of the coagulation cascade through the proteolytic cleavage of both Factor IX and Factor X. Complete absence of Factor VII activity is incompatible with life. Severe bleeding disorder phenotype is only observed in individuals homozygous for mutation in their F7 gene. Hemophilia A is an X-linked, recessive, bleeding disorder caused by a deficiency in the activity of coagulation Factor VIII. Affected individuals develop a variable phenotype of hemorrhage into joints and muscles, easy bruising and prolonged bleeding from wounds. The disorder is caused by heterogeneous mutations in the factor 8 gene which maps to Xq28.

This P207-C1 F9 probemix contains probes for all 8 exons of the F9 gene, spanning ~30 kb of genomic DNA on chromosome Xq27.1. Two probes are present for exon 8. The F7 gene (9 exons) spans ~15kb of genomic DNA and is located on 13q34. For all F7 exons a probe is present except for exon 3, but two probes are included for exon 8. The F8 gene (26 exons), spans ~180 kb of genomic DNA (isoform A) and is located on chromosome Xq28. For the F8 gene 7 probes are included. Finally, 16 reference probes are included in this probemix, detecting several different autosomal chromosomal locations.

This SALSA® MLPA® kit is designed to detect deletions/duplications of one or more sequences in the aforementioned gene(s). Deletions of a probe’s recognition sequence on the X-chromosome will lead to a complete absence of the corresponding probe amplification product in males, whereas female heterozygotes are recognisable by a 35 50% reduction in relative peak area. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a reduction in relative peak area, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings. We have no information on what percentage of defects in these genes is caused by deletions/duplications of complete exons. Finally, note that most defects in this gene are expected to be small (point) mutations which will not be detected by this SALSA® MLPA® test.  

Kontaktujte nás

BIOGEN PRAHA s.r.o.
Ke sv. Izidoru 2293/4A
140 00 PRAHA 4

Tel.: +420 241 401 693
Fax: +420 241 401 694
E-mail: biogen@biogen.cz

Novinky na e-mail